Interim report January – September 2020
The period in summary Third quarter July 1 – September 30, 2020 · Our marketing authorization application for Strangvac was submitted to the European Medicines Agency, EMA, at the end of February. During the third quarter, we have strengthened the dossier in the areas where EMA has asked for clarification. We are happy to report that we remain on track with our schedule and plan for a positive statement from EMA during the first half of 2021. · We focus on the preparations for the launch of Strangvac, which includes a distribution partner for Europe, outside regions where we